Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 190 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Branch V Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

NCT01873131
View directory record Official record
Conditions
Hemangioma
Interventions
topical timolol maleate, Pulsed dye laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Months
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 2, 2026, 3:48 AM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 2, 2026, 3:48 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 3 Interventional

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

NCT03451916
View directory record Official record
Conditions
Hip Fracture
Interventions
PLX-PAD, Placebo
Drug
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
0 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Sacramento, California • Denver, Colorado • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 2, 2026, 3:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00684996
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
etaracizumab, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

NCT03220737
View directory record Official record
Conditions
Cholera (Disorder)
Interventions
VAXCHORA (Cholera Vaccine, Live, Oral), Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
2 Years to 17 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
10
States / cities
Atlanta, Georgia • Lenexa, Kansas • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 2, 2026, 3:48 AM EDT
Recruiting Not applicable Interventional

Congenital Heart Disease Physical Activity Lifestyle Study V.2

NCT06003023
View directory record Official record
Conditions
Heart Defects, Congenital, Cardiovascular Disease Other
Interventions
Physical Activity Monitoring, Tailored Exercise Prescription, Healthy Lifestyle Education, Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior
Behavioral
Lead sponsor
Jamie Jackson
Other
Eligibility
15 Years to 25 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

NCT01896869
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ipilimumab, Vaccine, FOLFIRINOX
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

NCT00004092
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Not applicable Interventional

Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement

NCT05506878
View directory record Official record
Conditions
Opioid Use, Auriculotherapy, Pain, Abdominal, Cancer Pain, Liver Transplant
Interventions
NSS-2 BRIDGE, Sham NSS-2 BRIDGE
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2 Interventional

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930
View directory record Official record
Conditions
Prostate Cancer
Interventions
MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
36
States / cities
Hoover, Alabama • Springdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Not applicable Interventional

Web-based Physical Activity Intervention for Young Adult Cancer Survivors

NCT00791375
View directory record Official record
Conditions
Cancer
Interventions
Physical activity intervention
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 2, 2026, 3:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intervention to Improve Parent Communication About Sexuality

NCT07672067
View directory record Official record
Conditions
HIV/STI Incidence, Communication About Health Information
Interventions
Parents ASSIST
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years to 100 Years
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 3 Interventional Results available

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

NCT00369564
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
glutamic acid, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

NCT00976820
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 8 Years
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
17
States / cities
Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

NCT04516746
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD1222, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32,450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 1 Interventional

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

NCT04075747
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CPX-351, Venetoclax, Midostaurin, Enasidenib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Duarte, California • Palo Alto, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00011986
View directory record Official record
Conditions
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine Hydrochloride, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
4,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

NCT00774202
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 3 Interventional

A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions

NCT00371475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 2, 2026, 3:48 AM EDT
Enrolling by invitation Not applicable Interventional

Developing a Telehealth + mHealth Cannabis Use Intervention for Young Adults

NCT06661031
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Motivational Enhancement Therapy plus Ecological Momentary Intervention, Enhanced Usual Care
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 26 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 2, 2026, 3:48 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Sep 2, 2026, 3:48 AM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 3:48 AM EDT